SCHEDULE: Vanguard Group Reports 0% Stake in Travere Therapeutics

The Vanguard Group has reported a 0% beneficial ownership in Travere Therapeutics Inc. following an internal corporate realignment.

Summary

• The Vanguard Group filed an Amendment No. 9 to Schedule 13G for Travere Therapeutics Inc. Common Stock.
• The filing indicates that The Vanguard Group now beneficially owns 0 shares, representing 0% of the class of Common Stock.
• This change is attributed to an internal realignment within The Vanguard Group, Inc. on January 12, 2026.
• Following the realignment, certain subsidiaries or business divisions of The Vanguard Group, Inc. will report beneficial ownership separately (on a disaggregated basis).
• The Vanguard Group, Inc. no longer has, or is deemed to have, beneficial ownership over securities beneficially owned by these disaggregated subsidiaries.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event for Travere Therapeutics, as the change in beneficial ownership reported by The Vanguard Group is due to an internal corporate realignment rather than a specific investment decision related to the issuer's performance or prospects.

Future Outlook

No forward-looking statements or guidance for Travere Therapeutics Inc. are provided in this filing.

Management Comments

• The Vanguard Group, Inc. underwent an internal realignment on January 12, 2026.
• Certain subsidiaries or business divisions will now report beneficial ownership separately from The Vanguard Group, Inc. in reliance on SEC Release No. 34-39538.
• The Vanguard Group, Inc. no longer has, or is deemed to have, beneficial ownership over securities beneficially owned by such subsidiaries and/or business divisions.

Industry Context

StockSavvy.ai notes that Schedule 13G filings primarily reflect changes in institutional ownership. In this instance, the reported change is due to an internal restructuring at The Vanguard Group, rather than a direct investment decision regarding Travere Therapeutics Inc.'s operational performance or market position. This type of reporting adjustment is common for large asset managers undergoing internal reorganizations.

Stakeholder Impact

• Shareholders of Travere Therapeutics Inc. may observe a change in reported institutional ownership data, as The Vanguard Group's stake is now disaggregated among its subsidiaries.
• Investment professionals tracking institutional holdings will need to account for the disaggregated reporting from Vanguard's subsidiaries for a complete picture of their collective ownership in Travere Therapeutics Inc.

Next Steps

• The Vanguard Group's subsidiaries and/or business divisions will now report their beneficial ownership of Travere Therapeutics Inc. securities separately.

Key Dates

Keywords

Travere Therapeutics, Vanguard Group, Schedule 13G, beneficial ownership, institutional ownership, common stock, SEC filing, investment adviser